Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias

[1]  A. Tomkinson,et al.  Targeting Abnormal DNA Repair in Therapy-Resistant Breast Cancers , 2011, Molecular Cancer Research.

[2]  Steven S. Foster,et al.  Functional Interplay of the Mre11 Nuclease and Ku in the Response to Replication-Associated DNA Damage , 2011, Molecular and Cellular Biology.

[3]  H. Kantarjian,et al.  Practical advice for determining the role of BCR‐ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia , 2011, Cancer.

[4]  K. Ohnishi.  [Treatment of chronic myeloid leukemia with imatinib]. , 2011, Gan to kagaku ryoho. Cancer & chemotherapy.

[5]  B. Van Houten,et al.  Crucial roles for DNA ligase III in mitochondria but not in XRCC1-dependent repair , 2011, Nature.

[6]  R. Hehlmann,et al.  Treatment of chronic myeloid leukemia when imatinib fails , 2011, Expert opinion on pharmacotherapy.

[7]  J. Rehg,et al.  DNA Ligase III is critical for mtDNA integrity but not Xrcc1-mediated nuclear DNA repair , 2011, Nature.

[8]  Jinshui Fan,et al.  Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy. , 2010, Blood.

[9]  Jayanta Chaudhuri,et al.  CtIP promotes microhomology-mediated alternative end-joining during class switch recombination , 2010, Nature Structural &Molecular Biology.

[10]  Eric A. Hendrickson,et al.  Ku Regulates the Non-Homologous End Joining Pathway Choice of DNA Double-Strand Break Repair in Human Somatic Cells , 2010, PLoS genetics.

[11]  Alexander D. MacKerell,et al.  Identification and validation of human DNA ligase inhibitors using computer-aided drug design. , 2008, Journal of medicinal chemistry.

[12]  A. Ashworth,et al.  Targeted therapy for cancer using PARP inhibitors. , 2008, Current opinion in pharmacology.

[13]  P. Calsou,et al.  Effect of double-strand break DNA sequence on the PARP-1 NHEJ pathway. , 2008, Biochemical and biophysical research communications.

[14]  Alexander D. MacKerell,et al.  Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair. , 2008, Cancer research.

[15]  W. Kraus,et al.  Reciprocal Binding of PARP-1 and Histone H1 at Promoters Specifies Transcriptional Outcomes , 2008, Science.

[16]  Philippe Froguel,et al.  Array CGH analysis of copy number variation identifies 1284 new genes variant in healthy white males: implications for association studies of complex diseases. , 2007, Human molecular genetics.

[17]  Jiri Bartek,et al.  Human CtIP promotes DNA end resection , 2007, Nature.

[18]  M. Nussenzweig,et al.  A Backup DNA Repair Pathway Moves to the Forefront , 2007, Cell.

[19]  G. Chu,et al.  Cernunnos/XLF promotes the ligation of mismatched and noncohesive DNA ends , 2007, Proceedings of the National Academy of Sciences.

[20]  George Iliakis,et al.  PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways , 2006, Nucleic acids research.

[21]  M. Weinfeld,et al.  Involvement of polynucleotide kinase in a poly(ADP-ribose) polymerase-1-dependent DNA double-strand breaks rejoining pathway. , 2006, Journal of molecular biology.

[22]  Huichen Wang,et al.  DNA ligase III as a candidate component of backup pathways of nonhomologous end joining. , 2005, Cancer research.

[23]  P. Calsou,et al.  Involvement of Poly(ADP-ribose) Polymerase-1 and XRCC1/DNA Ligase III in an Alternative Route for DNA Double-strand Breaks Rejoining* , 2004, Journal of Biological Chemistry.

[24]  Yunmei Ma,et al.  A biochemically defined system for mammalian nonhomologous DNA end joining. , 2004, Molecular cell.

[25]  T. Skorski,et al.  BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. , 2004, Blood.

[26]  Susan Branford,et al.  Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. , 2003, Blood.

[27]  H. Mano,et al.  Analysis of Gene Expression Profiles in an Imatinib‐Resistant Cell Line, KCL22/SR , 2003, Stem cells.

[28]  G. Mufti,et al.  Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins. , 2003, Cancer research.

[29]  T. Skorski,et al.  BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability , 2002, Oncogene.

[30]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[31]  R. Fishel,et al.  Fusion Tyrosine Kinases Induce Drug Resistance by Stimulation of Homology-Dependent Recombination Repair, Prolongation of G2/M Phase, and Protection from Apoptosis , 2002, Molecular and Cellular Biology.

[32]  G. Mufti,et al.  Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer. , 2002, Cancer research.

[33]  R. Herrmann,et al.  High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. , 2002, Blood.

[34]  G. Hoser,et al.  DOES THE BCR/ABL‐MEDIATED INCREASE IN THE EFFICACY OF DNA REPAIR PLAY A ROLE IN THE DRUG RESISTANCE OF CANCER CELLS? , 2002, Cell biology international.

[35]  C. Koch,et al.  Mutation in the Glucose-6-phosphate Dehydrogenase Gene Leads to Inactivation of Ku DNA End Binding during Oxidative Stress* , 2002, The Journal of Biological Chemistry.

[36]  C. Peschel,et al.  BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study , 2002, The Lancet.

[37]  I. Osborne.  Fine-Tuning Fast Pulses , 2001, Science.

[38]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[39]  R. Salgia,et al.  The BCR/ABL Tyrosine Kinase Induces Production of Reactive Oxygen Species in Hematopoietic Cells* , 2000, The Journal of Biological Chemistry.

[40]  J. Melo,et al.  Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. , 2000, Blood.

[41]  J. Griffin,et al.  Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL–transformed hematopoietic cell lines , 2000 .

[42]  M. Varella‐Garcia,et al.  Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. , 2000, Blood.

[43]  M. Lieber,et al.  Activity of DNA ligase IV stimulated by complex formation with XRCC4 protein in mammalian cells , 1997, Nature.

[44]  J. Goldman,et al.  Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16‐year period , 1997, British journal of haematology.

[45]  A. Spiers.  Clinical manifestations of chronic granulocytic leukemia. , 1995, Seminars in oncology.

[46]  M. Löbrich,et al.  DNA double-strand break measurement in mammalian cells by pulsed-field gel electrophoresis: an approach using restriction enzymes and gene probing. , 1994, International journal of radiation biology.

[47]  M. Falzon,et al.  EBP-80, a transcription factor closely resembling the human autoantigen Ku, recognizes single- to double-strand transitions in DNA. , 1993, The Journal of biological chemistry.

[48]  S. Jackson,et al.  The DNA-dependent protein kinase: Requirement for DNA ends and association with Ku antigen , 1993, Cell.

[49]  J A Hardin,et al.  Mechanism of interaction between Ku protein and DNA. , 1986, The Journal of biological chemistry.

[50]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[51]  J. Culhane,et al.  Low energy x-ray map of Puppis A supernova remnant , 1973 .

[52]  Yu Zhang,et al.  An essential role for CtIP in chromosomal translocation formation through an alternative end-joining pathway , 2011, Nature Structural &Molecular Biology.

[53]  A. Tomkinson,et al.  consequences for the repair of DNA double strand breaks in chronic myeloid leukemia : α Up-regulation of WRN and DNA ligase III , 2008 .

[54]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2007, Nature.

[55]  J. Griffin,et al.  Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. , 2000, Blood.

[56]  J. Spivak,et al.  Commentary on and reprint of Nowell PC, Hungerford DA, A minute chromosome in human chronic granulocytic leukemia, in Science (1960) 132:1497 , 2000 .

[57]  Drinkwater Nr.  Experimental models and biological mechanisms for tumor promotion. , 1990 .

[58]  P. Nowell,et al.  A minute chromosome in human chronic granulocytic leukemia , 1960 .